Liquid Biopsy and Pancreas Cancer: Detection of AXL(+) CTCs (CTC-AXL-PANC)

Launched by UNIVERSITY HOSPITAL, MONTPELLIER · Apr 25, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a new way to detect certain cancer cells that break away from pancreatic tumors and travel through the bloodstream. These traveling cells, called circulating tumor cells (CTCs), can help doctors understand how the cancer is progressing and how well treatments are working. The study focuses on a specific marker called AXL, which is found on some aggressive cancer cells and is linked to worse outcomes. Researchers are comparing two different tests that look for these AXL-positive tumor cells in the blood to see if they give similar results in patients with advanced pancreatic cancer.

People who might be eligible for this study are adults diagnosed with metastatic pancreatic cancer who have not yet received any treatment and are about to start their first therapy. Participants will need to give their oral consent to join. If you take part, doctors will use a simple blood test (called a liquid biopsy) to detect these tumor cells. This test is non-invasive, meaning it doesn’t involve surgery or needles into the tumor itself, just a regular blood draw. The goal is to better understand how these tests work and potentially improve how doctors monitor pancreatic cancer in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • The patient is at least 18 years old;
• • Patients with pancreatic cancer with remote metastases, naïve of any treatment, that is, eligible for a first line of treatment;
• • Patients with oral consent
• Exclusion Criteria:
• • Non-affiliation or non-beneficiary of a Social Security regimen;
• • Frailty persons according to Article L1121-6 of the CSP;
• • Adult protected or unable to give consent as per Article L1121-8 of the CPMP;
• • Pregnant or lactating women as per MSC L1121-5.
• • Not included for monitoring difficulties (mutation, insufficient motivation, predictable poor compliance, priority associated pathology in care, etc.)